National Health (Pharmaceutical Benefits) Amendment Regulations 2010 (No. 4)

Overview

The National Health Act 1953, enacted by the Australian Parliament, governs the administration of public health in Australia and includes provisions for the regulation of pharmaceutical benefits. The National Health (Pharmaceutical Benefits) Amendment Regulations 2010 (No. 4) were introduced to address a specific issue concerning the staged statutory price reductions for pharmaceutical items listed in the Schedule of the Principal Regulations. These Regulations amend the reduction days and the percentage reductions for brands of pharmaceutical items in the F2T formulary, particularly focusing on ensuring that new bioequivalent brands trigger the remaining amount of the staged 25 per cent price reduction for all brands of the drug specified in Schedule 5. This reflects the Government's policy of applying price reductions to medicines in a competitive market while safeguarding single-brand medicines from unsustainable price reductions. The Regulations aim to give effect to this policy, ensuring that the price reductions are applied effectively and consistently across the pharmaceutical market.

Scope and Application

The National Health (Pharmaceutical Benefits) Amendment Regulations 2010 (No. 4) apply to pharmaceutical brands listed on the Pharmaceutical Benefits Scheme (PBS) Schedule, specifically those subject to a staged 25 per cent price reduction under the National Health Act 1953. This includes brands of lercanidipine, used in the treatment of hypertension, which have been amended to reflect the listing of new bioequivalent brands. The Regulations affect pharmaceutical companies and entities involved in the manufacture, supply, and distribution of these pharmaceutical items within Australia. They are designed to implement the government's policy of applying price reductions in a competitive market while ensuring that single-brand medicines do not face unsustainable price reductions. The Regulations have a national reach, applying across the Commonwealth of Australia, and are intended to provide a consistent framework for the staged price reductions as outlined in the Act. The Regulations do not specify any exclusions or exemptions, but they do clarify that the listing of a new bioequivalent brand triggers the application of the remaining staged price reduction to all brands of the drug specified in the Schedule.

Key Provisions

The National Health (Pharmaceutical Benefits) Amendment Regulations 2010 (No. 4) primarily amend the provisions relevant to the drug lercanidipine, which is used to treat hypertension, listed under the National Health (Pharmaceutical Benefits) Regulations 1960 (Principal Regulations). Section 99ACK of the National Health Act 1953 (Act) provides for a 25 per cent statutory price reduction staged over time for prescribed brands of pharmaceutical items in the F2T formulary, and Regulation 37B, together with Schedule 5 to the Principal Regulations, prescribes these brands, the reduction days for these brands, and the percentage reductions for each reduction day. These Regulations amend the reduction days and the amount of the percentage reductions for the existing PBS-listed brands of lercanidipine currently contained in Schedule 5, applying the remainder of the 25 per cent staged price reduction to the currently listed brands of lercanidipine on 1 December 2010. The Regulations impose specific obligations on pharmaceutical companies and entities involved in the pricing and listing of pharmaceutical items on the Pharmaceutical Benefits Scheme (PBS). Pharmaceutical companies must ensure that new brands of pharmaceutical items containing lercanidipine are listed on the PBS at the reduced price on 1 December 2010. This requirement aligns with the Government's policy of applying price reductions to medicines operating in a competitive market while protecting single-brand medicines from unsustainable price reductions. The Government’s intention is that a new bioequivalent brand listing of any of the drugs contained in Schedule 5 will trigger the application of any outstanding amount of the staged 25 per cent reduction for all brands of the drug specified in Schedule 5. This policy reflects the balance between competitive market pricing and the protection of single-brand medicines from unstainable price reductions. The Regulations do not explicitly outline specific offences or penalties for breach, but any failure to comply with the provisions could lead to civil or administrative consequences under the Act. The Act generally provides for penalties where regulations are contravened, although the exact penalties are not detailed within the Explanatory Statement. Such penalties could include fines or other civil remedies. It is also possible that breaches could lead to administrative actions, including potential delisting from the PBS, which could have significant financial and operational implications for pharmaceutical companies. The Act provides the Governor-General with the power to make regulations under Section 140, and these Regulations are intended to give effect to the Government's policy on staged price reductions for pharmaceutical items on the PBS. The Regulations do not require any specific conditions to be met before they can be made and come into effect the day after their registration on the Federal Register of Legislative Instruments. The legislative intent is to ensure that the staged price reductions are applied effectively and in a manner that balances market competition with the protection of single-brand medicines.